News Article | April 27, 2017
San Francisco, CA, April 27, 2017 --( The release of the new Language Studio™ NMT capabilities, complementing the existing Statistical Machine Translation (SMT) capabilities in the LexisNexis IP Solutions current workflow, provides for more accurate machine translations of IP documents. LexisNexis is once again asserting its market leadership position by offering the most innovative technologies and solutions available today to provide customers with industry leading Intellectual Property tools. “We have always pioneered advanced solutions to enhance our offerings, and our deployment of the new Language Studio™ NMT capabilities extends our existing partnership with Omniscien Technologies,” says Eric van Stegeren, Senior Director Technical Solutions and Managing Director of LexisNexis IP Solutions. “It provides us with the ability once again to establish our leadership position in the industry and provide a unique, high-quality offering to our clients,” van Stegeren continued. “Language Studio™ from Omniscien Technologies has served us well over the years, and the addition of NMT allows us the flexibility to select the best technology for the job dynamically, be it SMT, NMT or a combination of both. This represents a unique opportunity to achieve far better quality translations and solutions as part of our products,” says Laura Rossi, Manager Language Technology Solutions at LexisNexis IP Solutions. “We are truly honored and thrilled by the opportunity to be able to continue and extend our long-standing relationship with LexisNexis IP Solutions. Taking such a sophisticated new technology to market in an environment with such complexity as Intellectual Property data and the associated volumes of more than 100 billion words this year alone, requires a highly skilled team on both sides of the partnership as well as the effective collaboration which we have found in LexisNexis IP Solutions,” says Andrew Rufener, CEO of Omniscien Technologies. This collaboration between LexisNexis IP Solutions and Omniscien Technologies marks the largest commercial NMT deployment for intellectual property data translation between Asian and European languages in the world. Language Studio™ with Neural Machine Translation was announced for general availability on April 21 and is available to the global customer base of Omniscien Technologies in Language Studio™ Cloud as well as Language Studio™ Enterprise as an on-premise solution for customers requiring secure or high-volume installations. LexisNexis IP Solutions is part of LexisNexis® Legal & Professional. About LexisNexis® Legal & Professional LexisNexis Legal & Professional is a leading global provider of content and technology solutions that enable professionals in legal, corporate, tax, government, academic and non-profit organizations to make informed decisions and achieve better business outcomes. As a digital pioneer, the company was the first to bring legal and business information online with its Lexis® and Nexis® services. Today, LexisNexis Legal & Professional harnesses leading-edge technology and world-class content to help professionals work in faster, easier and more effective ways. Through close collaboration with its customers, the company ensures organizations can leverage its solutions to reduce risk, improve productivity, increase profitability and grow their business. LexisNexis Legal & Professional, which serves customers in more than 175 countries with 10,000 employees worldwide, is part of RELX Group, a global provider of information and analytics for professional and business customers across industries. About Omniscien Technologies Omniscien Technologies is a leading global supplier of high-performance and secure high-quality Language Processing, Machine Translation (MT) and Machine Learning technologies and services for content intensive applications. Our wide range of solutions serves clientele from various industries including the Localization Industry, Online Research Services, Publishing, eCommerce, Media, Online Travel, Technology, Enterprise and Government. Omniscien Technologies has gained a reputation for cutting edge solutions with its Language Studio™ platform. Depending upon the customer’s unique requirements, Language Studio™ can be deployed in a variety of ways to integrate with their in-house data processing and translation management systems, and it offers unparalleled levels of customization and control as well as feature rich pre- and post-processing, enabling customers with even the most complex data to achieve both high quality and high volume output to satisfy every use case. Omniscien Technologies has by far the most comprehensive and feature rich system in the market today. Covering 548 language pairs and with a number of industry specific solutions, Omniscien Technologies remains the partner of choice for customers with complex, high-volume bespoke data processing and machine translation needs. San Francisco, CA, April 27, 2017 --( PR.com )-- Omniscien Technologies (formerly Asia Online) today announced a partnership with LexisNexis to deploy Language Studio™ Neural Machine Translation (NMT) to further support the LexisNexis intellectual property workflow. This agreement offers the marketplace a superior customized solution based on the combination of expertise from leaders in machine translation and intellectual property solutions, Omniscien Technologies and LexisNexis IP.The release of the new Language Studio™ NMT capabilities, complementing the existing Statistical Machine Translation (SMT) capabilities in the LexisNexis IP Solutions current workflow, provides for more accurate machine translations of IP documents. LexisNexis is once again asserting its market leadership position by offering the most innovative technologies and solutions available today to provide customers with industry leading Intellectual Property tools.“We have always pioneered advanced solutions to enhance our offerings, and our deployment of the new Language Studio™ NMT capabilities extends our existing partnership with Omniscien Technologies,” says Eric van Stegeren, Senior Director Technical Solutions and Managing Director of LexisNexis IP Solutions. “It provides us with the ability once again to establish our leadership position in the industry and provide a unique, high-quality offering to our clients,” van Stegeren continued.“Language Studio™ from Omniscien Technologies has served us well over the years, and the addition of NMT allows us the flexibility to select the best technology for the job dynamically, be it SMT, NMT or a combination of both. This represents a unique opportunity to achieve far better quality translations and solutions as part of our products,” says Laura Rossi, Manager Language Technology Solutions at LexisNexis IP Solutions.“We are truly honored and thrilled by the opportunity to be able to continue and extend our long-standing relationship with LexisNexis IP Solutions. Taking such a sophisticated new technology to market in an environment with such complexity as Intellectual Property data and the associated volumes of more than 100 billion words this year alone, requires a highly skilled team on both sides of the partnership as well as the effective collaboration which we have found in LexisNexis IP Solutions,” says Andrew Rufener, CEO of Omniscien Technologies.This collaboration between LexisNexis IP Solutions and Omniscien Technologies marks the largest commercial NMT deployment for intellectual property data translation between Asian and European languages in the world.Language Studio™ with Neural Machine Translation was announced for general availability on April 21 and is available to the global customer base of Omniscien Technologies in Language Studio™ Cloud as well as Language Studio™ Enterprise as an on-premise solution for customers requiring secure or high-volume installations.LexisNexis IP Solutions is part of LexisNexis® Legal & Professional.About LexisNexis® Legal & ProfessionalLexisNexis Legal & Professional is a leading global provider of content and technology solutions that enable professionals in legal, corporate, tax, government, academic and non-profit organizations to make informed decisions and achieve better business outcomes. As a digital pioneer, the company was the first to bring legal and business information online with its Lexis® and Nexis® services. Today, LexisNexis Legal & Professional harnesses leading-edge technology and world-class content to help professionals work in faster, easier and more effective ways. Through close collaboration with its customers, the company ensures organizations can leverage its solutions to reduce risk, improve productivity, increase profitability and grow their business. LexisNexis Legal & Professional, which serves customers in more than 175 countries with 10,000 employees worldwide, is part of RELX Group, a global provider of information and analytics for professional and business customers across industries.About Omniscien TechnologiesOmniscien Technologies is a leading global supplier of high-performance and secure high-quality Language Processing, Machine Translation (MT) and Machine Learning technologies and services for content intensive applications. Our wide range of solutions serves clientele from various industries including the Localization Industry, Online Research Services, Publishing, eCommerce, Media, Online Travel, Technology, Enterprise and Government.Omniscien Technologies has gained a reputation for cutting edge solutions with its Language Studio™ platform. Depending upon the customer’s unique requirements, Language Studio™ can be deployed in a variety of ways to integrate with their in-house data processing and translation management systems, and it offers unparalleled levels of customization and control as well as feature rich pre- and post-processing, enabling customers with even the most complex data to achieve both high quality and high volume output to satisfy every use case. Omniscien Technologies has by far the most comprehensive and feature rich system in the market today.Covering 548 language pairs and with a number of industry specific solutions, Omniscien Technologies remains the partner of choice for customers with complex, high-volume bespoke data processing and machine translation needs. Click here to view the list of recent Press Releases from Omniscien Technologies
News Article | April 25, 2017
MELVILLE, N.Y.--(BUSINESS WIRE)--April 25, 2017-- Comtech Telecommunications Corp. (NASDAQ:CMTL) announced today that during its third quarter of fiscal 2017, its Tempe, Arizona-based subsidiary, Comtech EF Data Corp., which is part of Comtech’s Commercial Solutions segment, received a $1.8 million contract award extension for additional Advanced Time Division Multiple Access (TDMA) Interface Processor (ATIP) production terminals and Engineering Support Services from the Space and Naval Warfare Systems Command (SPAWAR). The ATIP is a Layer-2 Ethernet bridging device installed on ship, shore and submarine platforms in the Navy Multiband Terminal (NMT). The ATIP program is providing significant improvements to the Advanced Extremely High Frequency (AEHF) system's performance through dynamic bandwidth management, support for higher XDR data rates, and increased throughput. "This contract extension demonstrates the Navy’s continued confidence in the Comtech solution to support the ongoing deployment of ATIP throughout its fleet," commented Fred Kornberg, President and Chief Executive Officer of Comtech Telecommunications Corp. The contract extension also included exercising options under an Engineering Support Services option to participate in integration and test activities to validate the U.S. Navy’s planned PPPoE interface between the ATIP and Automated Digital Network System (ADNS). Comtech EF Data Corp. is the recognized global leader in satellite bandwidth efficiency and link optimization. The advanced communication solutions encompass the Heights Networking Platform, Advanced VSAT Solutions, Satellite Modems, RAN & WAN Optimization, Network & Bandwidth Management and RF products. The Company is recognized as a technology innovator, and has a reputation for exceptional product quality and reliability. The solutions enable commercial and government users to reduce OPEX/CAPEX and to increase throughput for fixed and mobile/transportable satellite-based applications. For more information, visit www.comtechefdata.com. Comtech Telecommunications Corp. designs, develops, produces and markets innovative products, systems and services for advanced communications solutions. The Company sells products to a diverse customer base in the global commercial and government communications markets. Certain information in this press release contains statements that are forward-looking in nature and involve certain significant risks and uncertainties. Actual results could differ materially from such forward-looking information. The Company's Securities and Exchange Commission filings identify many such risks and uncertainties. Any forward-looking information in this press release is qualified in its entirety by the risks and uncertainties described in such Securities and Exchange Commission filings.
News Article | November 26, 2016
Year to date investment of $2.5 million in R&D TORONTO, ONTARIO--(Marketwired - Nov. 25, 2016) - Eurocontrol Technics Group Inc. (TSX VENTURE:EUO)(OTCQB:EUCTF) ("Eurocontrol" or the "Company"), a Canadian public company specializing in the acquisition, development and commercialization of innovative test and measurement technologies for the authentication, verification and certification markets, announces that it has filed its interim financial statements and Management's Discussion and Analysis ("MD&A") for the third quarter ended September 30, 2016. The third quarter results reflect a 9% increase in fiscal year revenue, excluding discontinued operations, to $947,484 compared to $868,799 for the nine month period ended September 30, 2016. The Company recognized EBITDA of $14,335,515 ($702,562 as at September 30, 2015) and a gain on the sale of its former subsidiary of $16,484,172 ($Nil in 2015) resulting in net income of $12,542,059 for the nine months ending September 30, 2016 (net income of $223,749 in 2015). Included below is a summary table outlining earnings for the second quarter of 2016 compared to the corresponding 2015 period which is followed by a description of recent developments. Subsequent to the end of the second quarter, the Company received the first of the semi-annual guaranteed earn-out payments of $750,000 from SICPA SA. On January 4, 2016, the Company closed the sale of its wholly owned subsidiary, Global Fluids International (GFI) S.A. ("GFI") to SICPA Finance SA ("SICPA"), a subsidiary of SICPA SA, each a privately owned company based in Switzerland, in exchange for cash and post-closing earn-out payments and certain additional payments. In accordance with International Financial Reporting Standards ("IFRS"), the third quarter 2016 financial statements and MD&A are presented on an adjusted basis to include discontinued operations. For a reconciliation of discontinued operations, readers should refer to MD&A sections "Adjusted Revenue and Profit from Continuing Operations" and "Reconciliation of IFRS to Adjusted Results". Sales in the first nine months of 2016 increased 9% to $947,484 over 2015. In the nine months of 2016, Eurocontrol invested $1,050,989 in research and development to update existing Xenemetrix product lines, to develop new products and solutions for field applications and to enhance its manufacturing facilities and its quality control processes. This investment has been made to ensure that Xenemetrix maintains its position as a leader in the ED-XRF technology field and can continue to meet the high manufacturing and systems integration standards that its customers have come to expect. In addition to its core customer base, Xenemetrix has a long term supply and support agreement with SICPA to supply ED-XRF equipment to support Petromark™ fuel marking technology which relies on Xenemetrix ED-XRF technology to detect Petromark™ fuel markers. It is anticipated that sales for the balance of 2016 will remain consistent with 2015 revenue numbers with an increase anticipated in 2017 as SICPA gains market acceptance with its clients for the Petromark™ technology, the updated product line is rolled out and the expansion into the field of precision agriculture solidifies. In March 2016, Xenemetrix announced that it had entered into a Memorandum of Understanding with Netafim, an Israeli company that is the global leader in drip and micro-irrigation solutions for sustainable agricultural productivity, to develop a unique and innovative testing system utilizing Xenemetrix's ED-XRF technology for farmers and the greater farming community. The equipment solution and its calibration to the precision agriculture business has exceeded Netafim's test parameters and finalization of the method that have been collaboratively developed are underway. Significant progress has been made towards implementing new methods of measuring Nitrogen involving both hardware and software. Xenemetrix intends to initiate the process of commercialization that would provide an integrated solution for almond growers early in the second quarter of 2017. In respect of the Memorandum of Understanding that was announced in May 2016 between Eurocontrol and DigiFlex Ltd., a private Israeli company that holds patents in inks and printing, to form a joint venture between Xenemetrix and DigiFlex that will focus on developing technology to address security inks to provide a security solution to governments and product brands protection to industry, DigiFlex and Xenemetrix have successfully completed feasibility tests and Eurocontrol has conducted a market survey and business plan to establish the business opportunity. Collaboration on the technology is continuing and further updates will be provided as progress occurs. Xenemetrix remains focused on the development of new applications for its ED-XRF and establishing new marketing and distribution agreements in various regions. In the nine months ended September 30, 2016, Eurocontrol invested $1,460,665 in research and development in XwinSys. Earlier in 2016, XwinSys announced the finalized integration of its NMT (Noise-reduced Multilayer Thin-film Measurement System) technology (featured in Solid State Technology magazine) to respond to the evolving metrology and inspection needs of the semiconductor industry due to the advent of 3D stacking structures for continued miniaturization of devices at an affordable cost. In May 2016, XwinSys was granted a US patent on this unique multi-mode technology system that meets both fast in-line and in-depth metrology challenges without interrupting process flow. The XwinSys solution overcomes limitations of current technology that is used to measure thin and ultra-thin films, which can be a single layer of atoms of a specific material, and are a critical component in the construction of advanced semiconductor devices. With the XwinSys solution now finalized and demos, including the unveiling of the technology at SEMICON West this past summer where significant interest was generated, the XwinSys team continues to make progress towards commercialization of this disruptive technology that replaces the need for off-line analytical tasks. Bruce Rowlands, Chairman and CEO stated, "In addition to a modest increase in sales revenue from continued operations for the third quarter of 2015, we continued our R&D investments in both XwinSys and Xenemetrix positioning both companies for market expansion in 2017. As well, our development work with both Netafim and DigiFlex in our new initiatives in precision agriculture and chemical authentication, respectively have made excellent progress." Third Quarter 2016 Financial and Operating Highlights * Eurocontrol is a TSX Venture and OTCQB traded company that specializes in the acquisition, development and commercialization of innovative test and measurement technologies for the authentication, verification and certification markets. Eurocontrol has two wholly owned subsidiaries, Xenemetrix Ltd. and XwinSys Technology Development Ltd. and an agreement with SICPA S.A. for semi-annual earn-out payments of 5% (minimum $9 million over six years) on revenues generated from the oil and gas marking and monitoring field relating to the sale of its former subsidiary Global Fluids International (GFI) S.A. Xenemetrix is a leading designer, manufacturer and marketer of ED-XRF systems, a technology that is the most accurate and economic method for determining the chemical composition of many types of materials, including the analysis of petroleum oils and fuel. Xenemetrix has an exclusive long-term supply, maintenance and support agreement with SICPA/GFI to supply SICPA/GFI with Xenemetrix products and services related to the oil and gas marking and monitoring field. XwinSys has developed a patented, fully automated metrology system for the semiconductor industry that combines 2D and 3D image processing technology with Xenemetrix's ED-XRF technology. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. This press release contains forward-looking statements. More particularly, this press release contains statements. Forward-looking statements are frequently characterized by words such as "plan", "expect", "project", "intend", "believe", anticipate", "estimate", "may", "will", "would", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. The forward-looking statements are based on certain key expectations and assumptions made by Eurocontrol. Although Eurocontrol believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because Eurocontrol can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. In addition to other risks that may affect the forward-looking statements in this press release are those set out in Eurocontrol's management discussion and analysis of the financial condition and results of operations for the quarter ended September 30, 2016 and the year ended December 31, 2015 which are available on the Corporation's profile at www.sedar.com. The forward-looking statements contained in this press release are made as of the date hereof and Eurocontrol undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
News Article | November 14, 2016
Efficacy of the suture based NobleStitch™ EL for Patent Foramen Ovale (PFO) WASHINGTON, DC--(Marketwired - November 14, 2016) - Dr. Michael Mullen (Consultant Cardiologist, St. Bartholomew's Heart Hospital, Chief Clinical Officer of HeartStitch) presented preliminary clinical data of PFO closure using the NobleStitch™ EL, in 112 patients, at the 2016 Transcatheter Cardiovascular Therapeutics (TCT) Congress held in Washington, DC. http://content.onlinejacc.org/article.aspx?articleid=2576007 Attendees from around the world gathered in the Nation's Capital focusing on interventional cardiology therapies. Dr. Michael Mullen presented preliminary data on PFO closure with the suture based closure system NobleStitch EL in 3 separate sessions catching the attention of the structural heart interventionists. Dr. Mullen has extensive experience with the NobleStitch™ EL collaborating with NMT2 on the suture system's evolution. As a renowned Cardiologist and PFO expert, Dr. Mullen has been utilizing the NobleStitch™ EL for 8 years, most recently at St. Bartholomew's Hospital in London. The data presented from centres in the UK, Sweden, Germany, Italy, and Kazakhstan represented the multi-centre experience following commercial release of the NobleStitch EL system in Europe and Asia. In his presentations, to an audience of cardiologists and cardiac specialists from around the world, Dr. Mullen discussed that the NobleStitch™ EL is poised to be the device of choice for PFO closure. Dr. Mullen stated, "The NobleStitch is my first choice for PFO closure, it provides closure rates consistent with umbrella devices without the risks or long-term consequences of leaving leaving prosthetic devices in the heart. The Benefits of the NobleStitch over conventional PFO closure are slef evident. Their is minimal or no risk of complications including device migration, erosion, perforation, nickel allergy or atrial fibrillation. Additionally, the NobleStitch does not require any anti-coagulation, these collective benefits combined with the success we have demonstrated in the multi center data show that the NobleStitch technology is the new choice for PFO closure." Prof. Anthony Nobles, Chairman, CEO and Chief Clinical Specialist of Nobles Medical Technology commented, "With the renewed interest in PFO closure after the recent ruling of the FDA that PFO closure reduces recurrent stroke we have had a significant increase of interest in our NobleStitch Technology which has led to an increase in sales. The presentation of the multi center data now has given us the ability to show our products performance in a broad range of PFO's. This was the first time we presented our NobleStitch at the TCT, this is a major milestone for our company and we look forward to working with the many US based cardiologists that have approached us to provide the NobleStitch solution for their patients." The NobleStitch™ EL Suture System is a revolutionary technology in the treatment of structural heart disease of the atrial septum. The suture only system alleviates the need for any implanted device within the heart and therefore greatly reduces side effects associated with the traditional therapies. A PFO is a relatively common heart defect characterized by an unsealed tunnel between the right and left atria of the heart. This defect has been known to be present in anywhere between 27%-38% of people. However, in a number of cases, it is benign. The PFO is formed as a trace of the fetal circulation. When the chambers of a human heart begin to develop, a tunnel is made between the right and left atria, allowing blood to flow directly from the venous circulation to the arterial circulation, circumventing the non-functioning fetal lungs. Following birth, the pressure differential between the right and left atria changes with newly operational blood flow to the fully functioning lungs. Because of this, the tunnel eventually closes completely within the first few months. However, in some patients, the foramen ovale fails to seal and stays "patent". In patients with a Patent Foramen Ovale (PFO), the tunnel can reopen under elevated atrial pressure, such as coughing, or straining. A key issue with PFO is that it gives a pathway for blood clots to pass directly to the arterial circulation without being filtered out by the capillary bed of the lungs. A PFO can also let deoxygenated blood and certain chemicals cross over to the arterial side. The presence of a PFO has been linked to a number of clinical issues, mainly strokes, migraines and chronic fatigue. Developments are being made to solidify the link between PFO and strokes or migraines, and to identify patients that would benefit from PFO closure. An atrial septal defect (ASD) is a hole in the wall between the two upper chambers of your heart (atria). The condition is present from birth (congenital). Small atrial septal defects may close on their own during infancy or early childhood. Large and long-standing atrial septal defects can damage your heart and lungs. Small defects may never cause a problem and may be found incidentally. An adult who has had an undetected atrial septal defect for decades may have a shortened life span from heart failure or high blood pressure that affects the arteries in the lungs (pulmonary hypertension). Surgery may be necessary to repair atrial septal defects to prevent complications. Atrial septal aneurysm is a congenital cardiac abnormality that is characterized by saccular formation of the interatrial septum. Redundant atrial septal tissue results in bulging of the septum into either or both atria during the cardiac cycle. The diagnosis is best established with transesophageal echocardiography (TEE) since it can be easily missed with transthoracic echocardiography. Diagnostic criteria for ASA established by Hanley based on the appearance on echocardiography are: aneurysmal dilatation of the atrial septum protruding at least 1.5 cm beyond the plane of the atrial septum or phasic excursion of the interatrial septum during the cardiac cycle of at least 1.5 cm in total amplitude with a diameter at the base of the aneurysm of at least 1.5 cm. The condition can also be described using the Olivares-Reyes criteria, a classification based on the extent of excursion into each atrium. While the prevalence of ASA based on autopsy studies is <1%, the prevalence on TEE in non-selected patients is higher, in the range of 2% to 10%. Atrial septal aneurysm is clinically significant because of its association with cryptogenic stroke especially when there is a concurrent PFO. Approximately 70% of patients with ASA also have a PFO, while PFO is present in only 22% of patients without ASA. In one study, the combination of ASA and PFO was associated with a 33-fold higher risk of cryptogenic stroke. A meta-analysis has also found that ASA alone or ASA with PFO is associated with ischemic and cryptogenic strokes in patients <55 years of age. The strongest association is in those patients with both an ASA and a PFO. In patients <45 years of age with ischemic cerebral events, ASA should especially be suspected as a cardioembolic source. Mattioli and colleagues reported that 86% (43 of 50) of such patients had an ASA as the only possible etiology while 97% (42 of 43) of these younger patients with ASA also had a PFO. Patients with both ASA and PFO who have had a stroke are at substantial risk for recurrent stroke despite aspirin therapy. Mas and colleagues reported that the risk for recurrent stroke was 15% for patients with both PFO and ASA compared with 4.2% for patients with neither abnormality. These patients might benefit from more aggressive therapeutic strategies such as combination antiplatelet drugs, long-term anticoagulation or closure of the PFO. Nobles Medical Technology II, Inc. was founded by Prof. Anthony Nobles with the intent of leveraging its technologies in the PFO, ASD-closure, and vascular-suturing marketplace. The company does business under the name of Nobles Medical II (NMT II). Initial efforts of the company are focused on the innovative suture-based PFO closure system for closing the Patent Foramen Ovale (PFO), a tunnel between the right and left atria of the heart. The NobleStitch™ is approved for PFO Closure and Cardiovascular suturing in the European Union. The NobleStitch™ EL is FDA cleared for vascular suturing in the United States. NobleStitch™ EL is distributed worldwide by HeartStitch®, Inc. (HeartStitch® is a registered trademark of HeartStitch, Inc.). Covered by or for use under U.S. and international patents including one or more of U.S. Patent Nos. 5860990, 6117144, 6245079, 6551331, 6562052, 6733509, 7004952, 7090686, 7803167, 8197497, 8197510, 8246636, 8348962, 8372089, 8469975, 8496676, 8709020, and 9131938. For more on Nobles Medical Technologies II visit www.NoblesMed2.com The following files are available for download:
News Article | December 6, 2016
BEIJING, Dec. 6, 2016 /PRNewswire/ -- Leading smartphone company Meizu officially releases the all-new Meizu M5 Note, which features a full metal unibody design and a 5.5-inch Full HD display. As the latest member of Meizu's celebrated M-series, the M5 Note is designed for consumers who seek affordable smartphones with excellent industrial design and easy user experience. The new M5 Note has the classic full metal unibody that has gone through 12 steps of 3D sandblasting for a smoother touch, and comes in four colors: champagne gold, silver, grey, and blue. The speaker hole located at the bottom of the phone is carved in a rectangle shape and made by CNC equipment for more natural and even sounds. The 5.5-inch Full HD display with 2.5D glass features the latest smart eye-protective mode to ensure a more comfortable viewing experience. The display produces vivid colors and lively visuals. The powerful new generation 8-core 64-bit Cortex-A53 processor has a peak frequency of 1.8GHz. The M5 Note is equipped with either 3GB or 4GB RAM and users can choose between 16GB, 32GB, and 64GB of internal storage to satisfy every kind of user. Although the M5 Note is only 8.1mm thick, it is powered by a 4000mAh battery that can support 32 hours of talk time, eight hours of browsing on 4G or five hours of playing heavy games. Meizu specifically chose the safest battery cells from international suppliers to guarantee strong and stable performance. Backed by 18W of power, it takes just 90 minutes to charge the Meizu M5 Note. To better document the moments in life, the M5 Note has a 13 megapixel rear camera with 0.2s high-speed focusing. The 5 megapixel front camera comes with a real-time beautifying function that allows users to improve their selfies. The M5 Note also brings a fingerprint recognition experience that makes mobile payment easy and fast. It has a recognition angle of 360 and a response speed of 0.2 seconds. Aber Bai, President of Meizu, remarked that out of the M-series, which is defined as "Quality for Young," Meizu Note products sold more than 20 million during the period of two years in which they have been launched. The previous generation Note device achieved seven million in sales. "The M-series and the Note product lines have not only been recognized by the market, but are also seen as a leader in bringing high quality smartphones that are budget-friendly," said Bai. "This newly launched M-series M5 Note device is the first one in the series to be equipped with the NMT antenna that's mostly used in high-end flagship models. We believe this model will offer more value options for our users." The M5 Note will be available at RMB 899 (approx. USD 130.70) (3G+16G), RMB 999 (approx. USD 145.25) (3G+32G) and RMB 1,499 (approx. 217.95) (4G+64G). For more information about Meizu M5 Note, please visit: https://drive.google.com/drive/folders/0B9jmUcjnFk-GdHhZLU1aaENaYzA Founded in 2003, Meizu has become one of the most influential smartphone makers in the world. Meizu has developed a series of smartphones utilizing the Android-based Flyme operation system. The company now carries four smartphone lines: the PRO, MX, M and U-series. As of now, Meizu has released almost 30 smartphone models. According to the statistics from IC Insights, Meizu is the world's 11th largest mobile phone manufacturer in terms of unit sales. Meizu phones are characterized by their light, comfortable design, premium sound quality, high-definition camera, and simple, elegant user interface, combining performance, ease of use and functionality with the durability needed to survive the human experience. Meizu is currently officially available in Austria, Belgium, Brazil, Brunei, Bulgaria, Cambodia, Mainland China, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Latvia, Lithuania, Luxembourg, Malta, Myanmar, Netherlands, New Zealand, Poland, Portugal, Romania, Russia, Slovakia, Slovenia, Spain, Sweden, Ukraine and the United Kingdom. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/meizu-welcomes-new-m5-note-to-the-m-series-smartphone-family-300373596.html
News Article | February 20, 2017
BOISE, Idaho, Feb. 20, 2017 (GLOBE NEWSWIRE) -- The Idaho Center for Integrative Medicine (ICIM) (http://idahointegrativemedicine.com/), a leader in functional and holistic healthcare, is hosting a Customer Appreciation Day on February 21, 2017, from 4 p.m. to 7 p.m. The clinic is located at 3271 N. Milwaukee Street. In addition to complimentary refreshments and supplement samples, the staff will be available for free therapy, chair massages, office tours, and answer questions for participants. "We are excited to host this event as it gives us an opportunity to thank our patients for their support and let them know how important they are to us," said Dr. Noah Edvalson, Founder of ICIM. "This event will also allow us to introduce therapies to our customers that they may be unaware we have. Patients are our top priority and we look forward to providing them with the best care possible." In addition to celebrating customer appreciation, ICIM will present new members of the team, including Greg Howard and Randi Roark. Greg Howard, Nurse Practitioner, comes with a broad background working in both Family Medicine and Urgent Care settings. While most of his background and training is in traditional medicine, he has always been open minded about alternative medicine, and recognizes the need to support the body through nutrition and lifestyle modifications. Randi Roark, a nationally certified massage therapist and Bodyworker, practices a variety of massage techniques including Swedish, Deep Tissue, NMT/Trigger Point, Shiatsu, Cranial-Sacral Fascial Release, Tai/Yoga, and Integrative/Mindful Expression. Randi believes that every body is different and there is no one massage that suits all; therefore, her approach is tailored to each individual. She loves helping others and is enthusiastic about health and overall well-being. ICIM strives to use a functional and holistic approach to provide competent and progressive health care encompassing physical, nutritional, emotional, and energetic vitality in a compassionate and collaborative environment. The clinic treats the cause of disease using safe, natural, and effective therapies, while enriching the community with education, self-reliance, and self-empowerment. About The Idaho Center for Integrative Medicine The Idaho Center for Integrative Medicine effectively helps their clientele find the healthcare they need. Dr. Edvalson, founder and owner of ICIM, is trained in Chiropractic (a Certified Chiropractic Sports Physician and has received the Distinguished Service Award by the American Chiropractic Association Council on Sports Injuries and Physical Fitness), Naturopathy, Functional Medicine, Acupuncture, Ultraviolet Blood Irradiation, and much more. He is a Fellow of the American Academy of Ozone therapies, with the distinguished honor of being certified as an Advanced Prolozone Therapist. It is his passion and ICIM's goal to help offer a new hope to those suffering unnecessarily with chronic diseases.
News Article | March 1, 2017
CHICAGO--(BUSINESS WIRE)--The Nuveen Massachusetts Quality Municipal Income Fund (NYSE: NMT), as part of its ongoing leverage management process, has successfully completed the issuance of Variable Rate Demand Preferred (VRDP) shares in a privately negotiated exchange offer. In this transaction, the fund completed an exchange offer in which it refinanced its existing Series 2017 Variable Rate MuniFund Term Preferred (VMTP) shares on a one-for-one basis with new Series 1 VRDP shares with an initial special rate period ending February 28, 2018, and a term redemption date of March 1, 2047. As a result of the transaction, leverage of the fund remains unchanged and the fund has the following preferred shares outstanding: During the special rate period, the new Series 1 VRDP shares will not be remarketed by a remarketing agent, be subject to optional or mandatory tender events, or supported by a liquidity provider. Also, during this period, new Series 1 VRDP dividends will be set monthly at a floating rate based on a predetermined formula. The Series 1 VRDP shares are preferred securities of the fund and are senior, with priority in all respects, to the fund’s common shares in liquidation and as to payment of dividends. No VRDP shares have been registered under the Securities Act of 1933 (the Securities Act) or any state securities laws. Unless so registered, no VRDP shares may be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws. This press release is neither an offer to sell nor a solicitation of an offer to buy any of these securities. Nuveen provides investment solutions designed to help secure the long-term goals of individual investors and the advisors who serve them. Through the investment expertise of leading asset managers across traditional and alternative asset classes, Nuveen is committed to delivering consultative guidance that aligns with client needs. Funds distributed by Nuveen Securities, LLC, a subsidiary of Nuveen, LLC. For more information, please visit the Nuveen website at www.nuveen.com. The information contained on the Nuveen website is not a part of this press release. Certain statements made or referenced in this release may be forward-looking statements. Actual future results or occurrences may differ significantly from those anticipated in any forward-looking statements due to numerous factors. These include, but are not limited to: Nuveen and the closed-end funds managed by Nuveen and its affiliates undertake no responsibility to update publicly or revise any forward-looking statements. This notice is being provided pursuant to Regulation FD (Fair Disclosure) to inform the fund’s common and preferred shareholders of the completion of the fund’s privately negotiated exchange offer for preferred shares and designation of a special rate period for the new Series 1 VRDP shares.
News Article | March 22, 2016
The Australian CleanTech Index rose from 42.97 to 43.89 over the month of February recording a 2.2% gain. This compared to the S&P ASX200 loss of 2.5% and the S&P ASX Small Ordinaries Index gain of 0.7%. The Australian CleanTech 20 rose 2.3% for the month. The CleanTech Index continues to outperform the wider market over each of the longer periods reported in the table below. The 12-month performance now leads the ASX200 by 11.1%. The best performing sub-indices for the month were the Australian Renewable Energy Index with a 3.7% gain and the Australian Waste Index with a 3.6% gain. The weakest sub-index through February was the Australian Environment Index recording a loss of 4.0%. The market capitalisation of the 62 stocks in the Australian CleanTech Index is A$16.7 billion down from the March 2015 record of $18.9 billion but a long way up from its low of A$6.2 billion in July 2012. The month’s performance included 9 companies with gains of more than 10%. The greatest percentage gains were recorded by HRL Holdings (HRL), Neometals (NMT) and RedFlow (RFX). The greatest market capitalisation gain was recorded by Meridian Energy (MEZ). These gains were partially offset by 10 companies recording losses of more than 10% led by GO Energy Group (GOE), Kalina Power (KPO), Traffic Technologies (TTI) and Enerji (ERJ). The greatest market capitalisation loss was recorded by Mighty River Power (MYT). Get CleanTechnica’s 1st (completely free) electric car report → “Electric Cars: What Early Adopters & First Followers Want.” Come attend CleanTechnica’s 1st “Cleantech Revolution Tour” event → in Berlin, Germany, April 9–10. Keep up to date with all the hottest cleantech news by subscribing to our (free) cleantech newsletter, or keep an eye on sector-specific news by getting our (also free) solar energy newsletter, electric vehicle newsletter, or wind energy newsletter.
News Article | November 23, 2016
A leading applied science company has developed a ground-breaking new portable air particle sampling technology that promises a wide range of scientific and industrial applications, including monitoring environmental health, detecting pollutants and identifying Nano and micro particles in the atmosphere. Developed by British-based Ancon Technologies, the Aero Select is a compact, light-weight device that can detect particles across the aerosol range. The technology has promise for wide-ranging application across many industrial uses, such as occupational hygiene, environmental research, automotive manufacturing, atmospheric science, nanotechnology and microelectronics. The Aero Select provides researchers and technicians with a portable device that delivers laboratory accuracy in detecting the size, structure, morphology and chemical composition of aerosol particles. “The Aero Select a powerful tool for detecting the environmental impact or health risks associated with aerosol exposure,” said Wesley Baker, Commercial Director. “Our new product compresses advanced technology into a easy-to-operate device that gives users a number of options for measuring and monitoring aerosol levels. The possibilities for this technology are as widespread as they are fascinating.” The Aero Select will be useful in a wide-range of markets and industries, including: The Aero Select is powerful enough to measure particles from across the entire aerosol range, with the ability to determine concentrations of particles during processes like combustion and distinguish man-made particles against a background of naturally-occurring aerosols. The technology is accurate enough to detect target substances against background atmospheric aerosols by a factor of 20,000-to-1. The device’s size and shape make it convenient to transport, while a simplified installation process and a 24-hour programmable timer to provide an auto-start option if delayed operation is needed. With 12 cascading size channels, the Aero Select minimizes sampling errors caused by turbulence and corrosion, as the design reduces time and costs associated with analytical testing. “Whether it’s electronic and industrial manufacturing, scientific research or environmental monitoring, the Aero Select offers a powerful atmospheric testing tool that stands to improve productivity, efficiency and most of all, safety,” Baker said. Ancon Technologies’ Aero Select follows up on its revolutionary Nanotechnology Molecular Tagging system, which can be programmed to detect specific molecular markers. The NMT technology, and its variants, can be used to detect atmospheric levels of everything from chemicals used in explosives to the biological molecules that indicate disease. Ancon Technologies is headquartered in Canterbury, Kent, UK and has a satellite office in the U.S. in Bloomington, Minnesota.
News Article | February 17, 2017
Soft Power, a Korean software engineering company has recently released a real-time interpreting application that translates Korean into 10 different languages based on AI technology. The application is known as ManTong and users can activate it by simply talking into their mobile phones, and the app utilising Google Translate API, which applies a Neural Machine Learning AI (NMT) technology will translate the sentence instantaneously at the level of a professional interpreter. The application is also especially useful in noisy environments, which makes it suitable to use when abroad for short conversations. Since the app translates voice messages, one can simply talk into headphones that they are wearing and show the translated content to the other person without much hassle. Soft Power CEO Kim SuRang said, “Some interpretation or translation applications that exist in the market either cannot handle long sentences or directly translate voice recognized sentences. The users have to press the buttons for every sentence they would like to translate, which is very inconvenient in the situation where you are given instructions or counseling.” He further explained, “In this way, ManTong app solved the fundamental problem that occurs in existing interpretation and translation app, we created a technology that will tackle the problem at its root, as ManTong guarantees high quality and applicable interpretation and translation that supports a simultaneous two-way interpretation.” Software engineering expert Park JinHo, the director for Software Education Research Lab in Soongsil University also commented on the app, saying that “In fact, ManTong did not require a single line of code. It utilized ‘SmartMaker’, a software solution that expands upon language processing AI, and this technology can be used in a variety of other relevant fields such as voice recognition and speech synthesis to easily develop new applications.” Mantong is free for any personal use and can be downloaded via both the Google PlayStore and Apple AppStore. Hence, with a ManTong application on their smartphone, one is no longer restricted by a language barrier.